These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
503 related articles for article (PubMed ID: 26894799)
41. ESAs and irons in the pipeline: how do they differ? Beserab A Nephrol News Issues; 2013 Jun; 27(7):Supp 6-9. PubMed ID: 23855142 [No Abstract] [Full Text] [Related]
42. [Clinical relevance of anemia treatment in patients with chronic kidney disease]. Vuksanović-Mikulicić S; Mikolasević I; Jelić I; Bubić I; Sladoje-Martinović B; Racki S Acta Med Croatica; 2012 Jul; 66(3):193-202. PubMed ID: 23441533 [TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Tran DH; Wong GT; Chee YE; Irwin MG Expert Opin Biol Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24219367 [TBL] [Abstract][Full Text] [Related]
44. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842 [TBL] [Abstract][Full Text] [Related]
45. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. Musio F Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115 [TBL] [Abstract][Full Text] [Related]
46. Renal anemia: from incurable to curable. Sato Y; Yanagita M Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1239-48. PubMed ID: 23884144 [TBL] [Abstract][Full Text] [Related]
47. Current and future chemical therapies for treating anaemia in chronic kidney disease. Locatelli F; Del Vecchio L; Luise MC Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351 [TBL] [Abstract][Full Text] [Related]
48. [Factors affecting the response to erythropoiesis-stimulating agents]. Jauréguy M; Choukroun G Nephrol Ther; 2006 Sep; 2 Suppl 4():S274-82. PubMed ID: 17373270 [TBL] [Abstract][Full Text] [Related]
49. HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND. McCallum W; Weiner DE Clin J Am Soc Nephrol; 2022 Aug; 17(8):1255-1258. PubMed ID: 35790236 [No Abstract] [Full Text] [Related]
50. Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms. Miura T; Sato T; Yano T; Takaguri A; Miki T; Tohse N; Nishizawa K Cardiovasc Drugs Ther; 2023 Dec; 37(6):1175-1192. PubMed ID: 35150385 [TBL] [Abstract][Full Text] [Related]
51. Erythropoietin in cancer patients. Glaspy JA Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468 [TBL] [Abstract][Full Text] [Related]
52. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. Kim SM; Kim KM; Kwon SK; Kim HY J Korean Med Sci; 2016 Jan; 31(1):55-60. PubMed ID: 26770038 [TBL] [Abstract][Full Text] [Related]
53. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON. Wish JB Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360 [No Abstract] [Full Text] [Related]
54. Anaemia in CKD-treatment standard. Macdougall IC Nephrol Dial Transplant; 2024 Apr; 39(5):770-777. PubMed ID: 38012124 [TBL] [Abstract][Full Text] [Related]
55. Does TREAT give the boot to ESAs in the treatment of CKD anemia? Singh AK J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034 [No Abstract] [Full Text] [Related]
56. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease. Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294 [TBL] [Abstract][Full Text] [Related]